Kwality Pharmaceuticals delivered solid Q1FY27 results with net profit rising 3.2% year-on-year to ₹25.7 crore compared to ₹25 crore in Q1FY26, while revenue from operations increased 3.4% to ₹162.4 crore from ₹157.1 crore in the corresponding quarter last year. The company simultaneously raised its full-year FY27 revenue guidance to over ₹700 crore, up from the previous estimate of ₹650 crore, citing strong execution and improved visibility in regulated markets. The stock hit a new high of ₹3,130.85 on Monday, soaring 20% after the guidance revision. According to Business Standard, the stock has skyrocketed 183% thus far in the calendar year 2026 from a level of ₹1,108.25 on the BSE. The company's strong performance was driven by robust execution and clear visibility across its business segments.
Kwality Pharma delivered exceptional first-quarter results with consolidated net profit more than doubling to ₹25.62 crore compared to ₹11.93 crore in the corresponding quarter last year. According to reports from Business Standard, this translates to an year-on-year increase of more than 115%. The company's revenue from operations stood at ₹162.35 crore, representing a 45.63% increase from ₹111.48 crore recorded in the same period last year. The operating profit margin (OPM) expanded to 25.27% in Q1 FY2027, compared with 21.68% in the same quarter last year, indicating stronger operational efficiency even as revenue grew at a robust pace. The latest Q1FY27 results demonstrate EBITDA rising 3.9% to ₹41 crore compared to ₹39.5 crore in the corresponding period last year, with EBITDA margins improving to 27-28% for FY27, a significant expansion from the 24% achieved in FY26.
The pharmaceutical company demonstrated significant operational improvements during the quarter. As reported by Business Standard, PBDT increased 79% year-on-year to ₹38.98 crore from ₹21.79 crore in the year-ago period. The PBT rose 100% to ₹33.99 crore from ₹17.03 crore in the corresponding quarter last year. The Ebitda margin expanded to 25.3% in Q1 FY2027, compared with 21.8% in the same quarter last year, indicating stronger operating profitability even as revenue grew at a robust pace. The latest Q1FY27 results reflect EBITDA margins of 27-28% for FY27, with management highlighting that the revised guidance excludes potential contributions from the upcoming Hormone facility and Biologics platform, creating meaningful upside beyond the stated targets.
Kwality Pharmaceuticals is advancing its pipeline of complex formulations, biosimilars and niche injectable products, including the clinical development of Erythropoietin (EPO) and other biologic molecules. The company has completed over three bioequivalence (BE) studies during the quarter and maintains a pipeline of 40+ oral solid dosage molecules and three monoclonal antibodies. A dedicated hormone manufacturing plant (Unit 6) is under construction and is expected to be ready by November 2026. The biologics facility, which achieved pre-clinical success for Erythropoietin (Kwalipoietin), is on track for commercial launch in the first half of CY2027. Regulatory milestones contributed to positive momentum, with EU-GMP certification received for General and Beta Lactam plants, enabling expanded access to regulated European markets. New registrations were secured across Latin America, including Mexico and Colombia, as well as MENA and GCC regions, supporting the company's strategy of leveraging out-licensing and supply agreements.
The strong financial results and revised guidance triggered a significant market response with shares jumping over 20% in intraday trade. According to Business Standard, the stock was trading at ₹3,130.85 on Monday, up from its previous close. The stock has maintained strong momentum since the beginning of 2026, rallying over 183% during the period. The company's market capitalization stands at ₹3,252 crore as of the last trading session. Looking ahead, investors will be closely monitoring whether Kwality Pharma can sustain the pace of revenue growth and maintain the improved EBITDA margin in subsequent quarters. The company is targeting a net profit margin of approximately 15.3% in FY27 and aims to scale profitability in tandem with top-line growth. The industry's long-term outlook remains positive, supported by innovation, favourable demographics, rising healthcare expenditure, expanding insurance coverage and increasing global demand for affordable, high-quality healthcare solutions.
